lupus nephritis
Rheumatology · 2011–2026
4decisions
3medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| obinutuzumab Treatment of adult patients with active class III or IV lupus nephritis with or without class V disease who are receiving standard therapy with mycophenolate… | Mar 2026 | Recommended with restriction | no section in document |
| mycophenolic acid treatment of biopsy-proven WHO Class III, IV or V lupus nephritis in adults | Jul 2012 | Recommended with restriction | no section in document |
| mycophenolate sodium Induction and maintenance treatment of adult patients with biopsy-proven WHO Class III, IV or V lupus nephritis. | Jul 2012 | Recommended with restriction | no section in document |
| mycophenolate sodium treatment, initiated by a nephrologist, of a patient with biopsy-proven WHO Class III, IV or V lupus nephritis. | Nov 2011 | Deferred | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.